FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089652003> ?p ?o ?g. }

• W3089652003 endingPage "1890" @default.
• W3089652003 startingPage "1883" @default.
• W3089652003 abstract "Background: The purpose of this multicenter, randomized trial was to determine the optimal dosing regimen of tranexamic acid (TXA) to minimize perioperative blood loss in revision total hip arthroplasty. Methods: Six centers prospectively randomized 175 patients to 1 of 4 regimens: (1) 1-g intravenous (IV) TXA prior to incision (the single-dose IV group), (2) 1-g IV TXA prior to incision followed by 1-g IV TXA after arthrotomy wound closure (the double-dose IV group), (3) a combination of 1-g IV TXA prior to incision and 1-g intraoperative topical TXA (the combined IV and topical group), or (4) 3 doses totaling 1,950-mg oral TXA (the multidose oral group). Randomization was based on revision subgroups to ensure equivalent group distribution. An a priori power analysis (α = 0.05; β = 0.80) determined that 40 patients per group were required to identify a >1-g/dL difference in postoperative hemoglobin reduction between groups. Per-protocol analysis involved an analysis of variance, Fisher exact tests, and two 1-sided t tests for equivalence. Demographic and surgical variables were equivalent between groups. Results: No significant differences were found between TXA regimens when evaluating reduction in hemoglobin (3.4 g/dL for the single-dose IV group, 3.6 g/dL for the double-dose IV group, 3.5 g/dL for the combined IV and topical group, and 3.4 g/dL for the multidose oral group; p = 0.95), calculated blood loss (p = 0.90), or transfusion rates (14% for the single-dose IV group, 18% for the double-dose IV group, 17% for the combined group, and 17% for the multidose oral group; p = 0.96). Equivalence testing revealed that all possible pairings were statistically equivalent, assuming a >1-g/dL difference in hemoglobin reduction as clinically relevant. There was 1 venous thromboembolism, with no differences found between groups (p = 1.00). Conclusions: All 4 TXA groups tested had equivalent blood-sparing properties in the setting of revision total hip arthroplasty, with a single venous thromboembolism reported in this high-risk population. Based on the equivalence between groups, surgeons should utilize whichever of the 4 investigated regimens is best suited for their practice and hospital setting. Given the transfusion rate in revision total hip arthroplasty despite TXA utilization, further work is required in this area. Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence." @default.
• W3089652003 created "2020-10-08" @default.
• W3089652003 creator A5002665711 @default.
• W3089652003 creator A5013543724 @default.
• W3089652003 creator A5042462386 @default.
• W3089652003 creator A5050692387 @default.
• W3089652003 creator A5052132866 @default.
• W3089652003 creator A5054976158 @default.
• W3089652003 creator A5056944448 @default.
• W3089652003 creator A5067373513 @default.
• W3089652003 creator A5073571378 @default.
• W3089652003 creator A5087643045 @default.
• W3089652003 creator A5088286471 @default.
• W3089652003 date "2020-09-28" @default.
• W3089652003 modified "2023-10-11" @default.
• W3089652003 title "The Optimal Dosing Regimen for Tranexamic Acid in Revision Total Hip Arthroplasty" @default.
• W3089652003 cites W1984748046 @default.
• W3089652003 cites W1986082721 @default.
• W3089652003 cites W2040538032 @default.
• W3089652003 cites W2086064501 @default.
• W3089652003 cites W2103672870 @default.
• W3089652003 cites W2127110326 @default.
• W3089652003 cites W2129524235 @default.
• W3089652003 cites W2136098489 @default.
• W3089652003 cites W2167084145 @default.
• W3089652003 cites W2275715588 @default.
• W3089652003 cites W2341822850 @default.
• W3089652003 cites W2413403424 @default.
• W3089652003 cites W2592452759 @default.
• W3089652003 cites W2793448308 @default.
• W3089652003 cites W2801041049 @default.
• W3089652003 cites W2891658539 @default.
• W3089652003 cites W2913107319 @default.
• W3089652003 cites W2940538209 @default.
• W3089652003 cites W2947921014 @default.
• W3089652003 cites W2962791819 @default.
• W3089652003 cites W3136708880 @default.
• W3089652003 cites W4245151342 @default.
• W3089652003 doi "https://doi.org/10.2106/jbjs.20.00010" @default.
• W3089652003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33148955" @default.
• W3089652003 hasPublicationYear "2020" @default.
• W3089652003 type Work @default.
• W3089652003 sameAs 3089652003 @default.
• W3089652003 citedByCount "13" @default.
• W3089652003 countsByYear W30896520032021 @default.
• W3089652003 countsByYear W30896520032022 @default.
• W3089652003 countsByYear W30896520032023 @default.
• W3089652003 crossrefType "journal-article" @default.
• W3089652003 hasAuthorship W3089652003A5002665711 @default.
• W3089652003 hasAuthorship W3089652003A5013543724 @default.
• W3089652003 hasAuthorship W3089652003A5042462386 @default.
• W3089652003 hasAuthorship W3089652003A5050692387 @default.
• W3089652003 hasAuthorship W3089652003A5052132866 @default.
• W3089652003 hasAuthorship W3089652003A5054976158 @default.
• W3089652003 hasAuthorship W3089652003A5056944448 @default.
• W3089652003 hasAuthorship W3089652003A5067373513 @default.
• W3089652003 hasAuthorship W3089652003A5073571378 @default.
• W3089652003 hasAuthorship W3089652003A5087643045 @default.
• W3089652003 hasAuthorship W3089652003A5088286471 @default.
• W3089652003 hasConcept C126322002 @default.
• W3089652003 hasConcept C141071460 @default.
• W3089652003 hasConcept C168563851 @default.
• W3089652003 hasConcept C204243189 @default.
• W3089652003 hasConcept C2777288759 @default.
• W3089652003 hasConcept C2779637338 @default.
• W3089652003 hasConcept C2781413609 @default.
• W3089652003 hasConcept C2991743468 @default.
• W3089652003 hasConcept C31174226 @default.
• W3089652003 hasConcept C42219234 @default.
• W3089652003 hasConcept C71924100 @default.
• W3089652003 hasConceptScore W3089652003C126322002 @default.
• W3089652003 hasConceptScore W3089652003C141071460 @default.
• W3089652003 hasConceptScore W3089652003C168563851 @default.
• W3089652003 hasConceptScore W3089652003C204243189 @default.
• W3089652003 hasConceptScore W3089652003C2777288759 @default.
• W3089652003 hasConceptScore W3089652003C2779637338 @default.
• W3089652003 hasConceptScore W3089652003C2781413609 @default.
• W3089652003 hasConceptScore W3089652003C2991743468 @default.
• W3089652003 hasConceptScore W3089652003C31174226 @default.
• W3089652003 hasConceptScore W3089652003C42219234 @default.
• W3089652003 hasConceptScore W3089652003C71924100 @default.
• W3089652003 hasIssue "21" @default.
• W3089652003 hasLocation W30896520031 @default.
• W3089652003 hasOpenAccess W3089652003 @default.
• W3089652003 hasPrimaryLocation W30896520031 @default.
• W3089652003 hasRelatedWork W1979403001 @default.
• W3089652003 hasRelatedWork W2117673436 @default.
• W3089652003 hasRelatedWork W2314711013 @default.
• W3089652003 hasRelatedWork W2315138922 @default.
• W3089652003 hasRelatedWork W2317612395 @default.
• W3089652003 hasRelatedWork W2328659429 @default.
• W3089652003 hasRelatedWork W2800022962 @default.
• W3089652003 hasRelatedWork W2962791819 @default.
• W3089652003 hasRelatedWork W3009399736 @default.
• W3089652003 hasRelatedWork W3086340038 @default.
• W3089652003 hasVolume "102" @default.
• W3089652003 isParatext "false" @default.
• W3089652003 isRetracted "false" @default.

• next